AMERI Holdings is Now Enveric Biosciences
Hit enter to search or ESC to close
Enveric BiosciencesEnveric BiosciencesEnveric Biosciences
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Collaborations
  • Science
    • CBD Combination Therapies
    • Intellectual Property
  • Pipeline
    • Development Programs
    • Enabling Partnership with Tikun Olam
    • Glioblastoma Multiforme
    • Radiation Dermatitis
    • Chemotherapy-Induced Peripheral Neuropathy
    • Additional Development Programs
  • News & Media
  • Investors
    • Investor Overview
    • Press Releases
    • Events + Presentations
    • Company Information
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • News Alerts
  • Contact
    • General Inquiries
    • Career Opportunities
    • Partnership Inquiries
Investors

Press Releases

Overview
Press Releases     
Events + Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
News Alerts

Recent Press Releases

Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021
April 01, 2021

Enveric Biosciences Appoints Dr. Douglas D. Lind to Company's Board of Directors
March 18, 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in March
March 15, 2021

Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech
March 10, 2021

Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs
February 25, 2021

Enveric Biosciences Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock
February 12, 2021

Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering
February 09, 2021

Enveric Biosciences Issues Shareholder Letter Providing Strategic Vision for Advancing Novel Prescription Supportive Care Cancer Therapies
January 19, 2021

Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering
January 15, 2021

Enveric Biosciences Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 12, 2021

Enveric Newsroom

Sign Up for Updates

© 2021 Enveric Biosciences | Terms of Use | Privacy Policy
Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.

  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Collaborations
  • Science
    • CBD Combination Therapies
    • Intellectual Property
  • Pipeline
    • Development Programs
    • Enabling Partnership with Tikun Olam
    • Glioblastoma Multiforme
    • Radiation Dermatitis
    • Chemotherapy-Induced Peripheral Neuropathy
    • Additional Development Programs
  • News & Media
  • Investors
    • Investor Overview
    • Press Releases
    • Events + Presentations
    • Company Information
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • News Alerts
  • Contact
    • General Inquiries
    • Career Opportunities
    • Partnership Inquiries